CYP93G2 Antibody

What is CYP93G2 and why would researchers need antibodies against it?

CYP93G2 is a cytochrome P450 enzyme functioning as a flavanone 2-hydroxylase that plays a critical role in C-glycosylflavone biosynthesis in rice. The enzyme consists of 518 amino acids with a calculated pI of 8.177 and is encoded by Os06g01250 . CYP93G2 catalyzes the conversion of flavanones (such as naringenin and eriodictyol) to their corresponding 2-hydroxyflavanones, which serve as essential intermediates for C-glycosylation .

Antibodies against CYP93G2 would serve multiple research purposes:

• Studying expression patterns across different plant tissues and developmental stages

• Investigating subcellular localization of the enzyme

• Examining protein-protein interactions in flavonoid biosynthetic pathways

• Evaluating enzyme levels in wild-type versus mutant plants

• Immunoprecipitation for functional studies or protein complex analysis

Rice CYP93G2 T-DNA insertion mutants show substantially reduced C-glycosylflavone accumulation, confirming this enzyme's critical role in flavonoid biosynthesis . Antibodies would provide tools to further characterize this pathway and potentially explore similar mechanisms in other cereal crops.

What are the most critical experimental validations for confirming CYP93G2 antibody specificity?

Ensuring antibody specificity is crucial for reliable experimental results. For CYP93G2 antibodies, researchers should implement these essential validation steps:

• Western blot analysis with positive and negative controls:

  • Positive controls: Extracts from rice leaves known to express CYP93G2

  • Negative controls: Extracts from CYP93G2 T-DNA insertion mutant rice plants

  • Expected molecular weight: ~58 kDa (calculated from the 518 amino acid sequence)

• Recombinant protein validation:

  • Test against purified recombinant CYP93G2 expressed in heterologous systems

  • Verify dose-dependent binding across a concentration gradient

  • Compare with other recombinant cytochrome P450 enzymes to assess cross-reactivity

• Flow cytometry-based validation approaches:

  • Develop quantitative workflows similar to those used for other antibodies

  • Compare staining profiles between wild-type and knockout samples

  • Use statistical analysis to distinguish specific from non-specific binding

• Pre-absorption controls:

  • Pre-incubate antibody with recombinant CYP93G2 before testing

  • Absorption should substantially reduce or eliminate signal in positive samples

  • Include partial absorption titrations to demonstrate specificity

• Cross-reactivity assessment:

  • Test against closely related enzymes, particularly other CYP93 family members

  • Evaluate binding to flavanone 2-hydroxylases from different plant species

  • Check for reactivity with common P450 conserved domains

Comprehensive validation using multiple complementary approaches provides the strongest evidence for antibody specificity, which is essential before proceeding with experimental applications.

What expression patterns and cellular localization would be expected for CYP93G2 in different plant tissues?

Based on available research data, CYP93G2 exhibits specific expression patterns that correlate with C-glycosylflavone accumulation:

CYP93G2 is strongly expressed in wild-type rice leaves, as demonstrated by RT-PCR analysis . The expression pattern correlates directly with the accumulation of C-glycosylflavones, particularly isovitexin derivatives. In CYP93G2 knockout plants, while tricin levels remain comparable to wild-type, there is a marked reduction in isovitexin accumulation .

Regarding subcellular localization, as a cytochrome P450 enzyme, CYP93G2 would be expected to localize to the endoplasmic reticulum membrane, as is typical for plant P450s involved in secondary metabolism. Researchers should anticipate this localization pattern when designing immunofluorescence or subcellular fractionation experiments.

When using CYP93G2 antibodies, researchers should expect the strongest immunoreactivity in leaf tissues, with potential detection in other vegetative tissues depending on the developmental stage and environmental conditions.

How should researchers troubleshoot non-specific binding with CYP93G2 antibodies?

Non-specific binding is a common challenge with plant samples due to their complex matrix and abundant secondary metabolites. Researchers can address this issue through these methodological approaches:

• Optimize blocking conditions:

  • Test different blocking agents (BSA, non-fat milk, commercial blockers)

  • Increase blocking time (from 1 hour to overnight)

  • Add 0.1-0.3% Tween-20 to reduce hydrophobic interactions

  • Consider specialized blockers designed for plant samples

• Adjust antibody parameters:

  • Perform titration experiments to determine optimal antibody concentration

  • Extend primary antibody incubation time at lower concentrations

  • Test different antibody diluents to improve signal-to-noise ratio

  • Consider using Fab fragments if full IgG causes high background

• Enhance washing protocols:

  • Increase wash buffer stringency (150-500 mM NaCl)

  • Extend washing times (5-10 minutes per wash)

  • Add detergents like Triton X-100 (0.1-0.5%) to wash buffers

  • Implement additional washing steps after both primary and secondary antibody incubations

• Sample preparation refinements:

  • Include PVPP (polyvinylpolypyrrolidone) to remove phenolic compounds

  • Add protease inhibitors to prevent epitope degradation

  • Clear lysates thoroughly by high-speed centrifugation

  • Pre-absorb samples with beads/matrix used in immunoprecipitation

• Flow cytometry-based troubleshooting:

  • Apply flow cytometry methods for antibody validation

  • Compare mean fluorescence intensity between positive and negative samples

  • Use statistical approaches to establish threshold for positive binding

For persistent issues, consider developing or obtaining alternative antibodies targeting different epitopes of CYP93G2, as certain regions may be more prone to non-specific interactions.

What controls should be included when performing immunoprecipitation with CYP93G2 antibodies?

Robust controls are essential for reliable immunoprecipitation (IP) experiments with CYP93G2 antibodies:

• Input controls:

  • Save an aliquot (~5%) of pre-cleared lysate before immunoprecipitation

  • Use for comparison to IP fraction to assess enrichment efficiency

  • Verify presence of target protein by western blot

• Negative controls for non-specific binding:

  • IgG control: Perform parallel IP with non-specific IgG of same species/isotype

  • Beads-only control: Process sample without primary antibody

  • Pre-immune serum control (if using polyclonal antibodies)

• Genetic controls:

  • CYP93G2 T-DNA insertion mutant rice plants as definitive negative controls

  • Plants overexpressing CYP93G2 as positive controls (e.g., transgenic Arabidopsis)

  • Wild-type samples from tissues with known expression patterns

• Technical validation controls:

  • Pre-absorption control: Antibody pre-incubated with recombinant CYP93G2

  • Serial dilution of input to assess linearity of detection

  • Mock IP from buffer-only samples to identify contaminants from reagents

• Specific controls for co-immunoprecipitation studies:

  • Reverse IP with antibodies against potential interacting partners (e.g., OsCGT)

  • Competition assays with recombinant proteins

  • Crosslinking controls if chemical crosslinkers are used

When investigating CYP93G2 interactions with enzymes like OsCGT (which functions downstream in the same pathway) , these controls become particularly important for distinguishing genuine interactions from non-specific associations.

How can computational modeling help predict optimal epitopes for CYP93G2 antibody development?

Computational modeling provides powerful approaches for designing highly specific CYP93G2 antibodies:

• Structural analysis and epitope prediction:

  • Analyze the CYP93G2 sequence (518 amino acids) to identify surface-exposed regions

  • Generate homology models based on related crystallized P450 structures

  • Apply epitope prediction algorithms that consider hydrophilicity, flexibility, and accessibility

  • Focus on regions unique to CYP93G2 compared to other CYP93 family members

• Machine learning approaches for antibody-antigen interactions:

  • Implement biophysics-informed models similar to those described for other antibodies

  • Identify distinct binding modes that differentiate between specific and cross-reactive epitopes

  • Train computational models using experimental selection data to predict optimal antibody-antigen interactions

  • Apply these models to "generate antibody variants not present in the initial library that are specific to a given combination of ligands"

• Sequence-based analysis focusing on functional domains:

  • Analyze CYP93G2-specific regions versus conserved P450 domains

  • Avoid targeting the highly conserved heme-binding motif to minimize cross-reactivity

  • Identify regions that diverge from dicot FNSII and legume F2H sequences

  • Map the diagnostic sequence signatures (Pro hinge region, oxygen-binding pocket) to identify unique variations

• Application of structural biology insights:

  • Model substrate binding sites based on known enzymatic activities (conversion of naringenin/eriodictyol to 2-hydroxyflavanones)

  • Identify conformational changes that might occur during catalysis

  • Design antibodies that selectively recognize specific conformational states

By employing these computational approaches, researchers can significantly accelerate antibody development while increasing the likelihood of generating highly specific antibodies against CYP93G2.

What strategies can be employed to develop antibodies that distinguish between CYP93G2 and closely related CYP93 family members?

Developing antibodies with high specificity for CYP93G2 over related family members requires sophisticated strategies:

• Epitope selection based on sequence divergence:

  • Perform multiple sequence alignment of CYP93G2 with other CYP93 enzymes

  • Identify regions unique to CYP93G2, particularly those that diverge from related rice enzymes

  • Target sequences that differ from the CYP93B subfamily, which consists of dicot flavone synthase II enzymes

  • Focus on variable loops rather than conserved catalytic domains

• Phage display selection with negative screening:

  • Implement selection strategies similar to those described for other specific antibodies

  • Include negative selection steps against closely related enzymes

  • Perform multiple rounds of selection with increasing stringency

  • Design library diversity with focus on complementarity-determining regions (CDRs)

• Application of biophysics-informed models:

  • Train models on experimentally selected antibodies to identify distinct binding modes

  • Use these models to predict and generate antibody variants with desired specificity profiles

  • Apply computational design to optimize antibody sequences for discriminating between highly similar epitopes

  • Test model-predicted variants experimentally to validate specificity

• Structural biology-guided approaches:

  • Target structural features unique to CYP93G2

  • Focus on surface-exposed regions that differ in charge, hydrophobicity, or conformation

  • Design antibodies against regions involved in substrate specificity

  • Consider regions important for the specific hydroxylation pattern catalyzed by CYP93G2

• Rigorous validation with genetic controls:

  • Use CYP93G2 T-DNA insertion mutant rice plants as negative controls

  • Express recombinant CYP93G1 and other related enzymes for cross-reactivity testing

  • Perform competition assays with recombinant proteins

  • Validate in multiple experimental formats (western blot, immunoprecipitation, immunohistochemistry)

These strategies, when combined with rigorous validation, provide the best approach for developing antibodies that specifically recognize CYP93G2 while excluding closely related family members.

How might post-translational modifications of CYP93G2 affect antibody recognition and experimental outcomes?

Post-translational modifications (PTMs) can significantly impact antibody recognition of CYP93G2, affecting experimental results:

• Potential PTMs affecting cytochrome P450 enzymes like CYP93G2:

  • Phosphorylation: May regulate enzyme activity or protein-protein interactions

  • Glycosylation: Could affect protein stability or membrane association

  • Ubiquitination: Involved in protein turnover regulation

  • Membrane anchor modifications: Critical for ER localization typical of P450s

• Effects on epitope accessibility and antibody binding:

  • PTMs near epitopes may create steric hindrance preventing antibody access

  • Modifications can induce conformational changes affecting three-dimensional epitopes

  • Charge alterations from phosphorylation may affect antibody-antigen electrostatic interactions

  • Glycosylation can mask epitopes, particularly in native immunoprecipitation experiments

• Experimental strategies to address PTM variability:

  • Generate multiple antibodies targeting different regions of CYP93G2

  • Develop modification-specific antibodies for studying regulatory mechanisms

  • Use denaturing conditions in western blots to minimize conformational epitope issues

  • Compare antibody binding in different extraction conditions that preserve or disrupt PTMs

• Analytical approaches to assess PTM impact:

  • Treat samples with phosphatases, glycosidases, or deubiquitinating enzymes before analysis

  • Perform 2D gel electrophoresis to separate differently modified forms

  • Use mass spectrometry to characterize PTM patterns in different tissues/conditions

  • Compare CYP93G2 expressed in different systems (bacterial, yeast, plant) with varying PTM capabilities

• Biological significance considerations:

  • PTMs may vary across different plant tissues, developmental stages, or stress conditions

  • Modification patterns could influence CYP93G2 activity in converting flavanones to 2-hydroxyflavanones

  • Potential regulatory role in coordinating CYP93G2 activity with OsCGT in the C-glycosylflavone pathway

Researchers should consider that observed differences in antibody binding might reflect biologically relevant PTM changes rather than experimental artifacts, potentially revealing regulatory mechanisms in flavonoid biosynthesis.

What approaches can be used to study protein-protein interactions involving CYP93G2 in flavonoid biosynthesis pathways?

Understanding protein-protein interactions is crucial for elucidating the functional organization of flavonoid biosynthesis pathways involving CYP93G2:

• Co-immunoprecipitation (Co-IP) approaches:

  • Use anti-CYP93G2 antibodies to precipitate protein complexes from plant extracts

  • Identify interaction partners through mass spectrometry analysis

  • Focus on potential interactions with OsCGT, which functions downstream of CYP93G2

  • Compare interaction patterns in wild-type versus metabolic pathway mutants

• Proximity-dependent labeling techniques:

  • Fuse CYP93G2 with BioID or TurboID enzymes for proximity-dependent biotinylation

  • Express fusion proteins in rice or heterologous systems

  • Identify proteins in close proximity through streptavidin pulldown and mass spectrometry

  • Compare interactome in different tissues or under different conditions

• Fluorescence-based interaction studies:

  • Implement bimolecular fluorescence complementation (BiFC) for in vivo interaction visualization

  • Apply Förster resonance energy transfer (FRET) to measure direct protein associations

  • Conduct fluorescence lifetime imaging microscopy (FLIM) for quantitative assessment

  • Correlate interaction patterns with subcellular localization and metabolite production

• Crosslinking mass spectrometry (XL-MS):

  • Apply chemical crosslinkers to stabilize transient interactions

  • Perform immunoprecipitation with CYP93G2 antibodies

  • Identify crosslinked peptides through specialized mass spectrometry approaches

  • Map interaction interfaces at amino acid resolution

• Functional validation of interactions:

  • Reconstitute enzymatic pathways with recombinant proteins in vitro

  • Compare activity of isolated enzymes versus enzyme complexes

  • Develop split-reporter assays to monitor interactions in plant cells

  • Correlate interaction disruption with metabolic consequences

These approaches can reveal how CYP93G2 functions within metabolic complexes to generate 2-hydroxyflavanone substrates for C-glucosylation by OsCGT in planta , potentially identifying regulatory mechanisms and metabolic channeling in flavonoid biosynthesis.

How can researchers develop antibodies specific to different conformational states of CYP93G2?

Developing conformation-specific antibodies for CYP93G2 requires sophisticated approaches:

• Stabilization of distinct conformational states:

  • Substrate-bound form: Prepare CYP93G2 in complex with naringenin or eriodictyol

  • Product-bound form: Stabilize with 2-hydroxyflavanones

  • Different redox states: Prepare enzyme in oxidized versus reduced forms

  • Transition state analogs: Design compounds that mimic reaction intermediates

  • NADPH-bound state: Prepare enzyme in the presence of the cofactor

• Selection strategies for conformation-specific antibodies:

  • Implement phage display selections with conformationally locked antigens

  • Apply negative selection against unwanted conformations

  • Utilize computational approaches to design antibodies with "customized specificity profiles"

  • Screen antibody libraries under conditions that stabilize specific conformations

• Biophysics-informed modeling approaches:

  • Train models to distinguish binding modes associated with different conformational states

  • Apply computational design principles to optimize antibody sequences for conformational discrimination

  • Use these models to "predict and generate specific variants beyond those observed in the experiments"

  • Validate model predictions with experimental binding studies

• Validation of conformation specificity:

  • Develop assays comparing antibody binding to various conformational states

  • Use spectroscopic techniques to confirm that antibody binding preserves the target conformation

  • Perform differential scanning fluorimetry to assess stabilization of specific conformations

  • Conduct enzymatic activity assays to determine if antibody binding affects function

• Applications in CYP93G2 research:

  • Track conformational changes during the catalytic cycle

  • Identify conditions that promote specific conformations in vivo

  • Study how protein-protein interactions with partners like OsCGT affect CYP93G2 conformation

  • Investigate the relationship between conformation and catalytic efficiency in converting flavanones to 2-hydroxyflavanones

Conformation-specific antibodies would be particularly valuable for understanding the catalytic mechanism of CYP93G2 and the structural dynamics underlying its role in C-glycosylflavone biosynthesis in rice.

What are the optimal protocols for using CYP93G2 antibodies in immunoprecipitation experiments?

Optimized immunoprecipitation (IP) protocols for CYP93G2 antibodies should consider the following methodological details:

Sample preparation from plant tissues:

• Harvest fresh tissue (preferably leaves showing high CYP93G2 expression )

• Flash-freeze in liquid nitrogen and grind to a fine powder

• Extract with a suitable buffer containing:

  • 50 mM Tris-HCl, pH 7.5 (optimal for CYP93G2 activity )

  • 150 mM NaCl

  • 1% NP-40 or 0.5% Triton X-100

  • 1 mM EDTA

  • Protease inhibitor cocktail

  • 5% glycerol to stabilize protein structure

  • 1 mM DTT to maintain reducing conditions

• Clarify lysate by centrifugation (14,000 × g, 15 min, 4°C)

Immunoprecipitation procedure:

• Pre-clear lysate with protein A/G beads (30 min, 4°C) to reduce non-specific binding

• Incubate pre-cleared lysate with CYP93G2 antibody (2-5 μg per 1 mg protein) overnight at 4°C

• Add protein A/G beads and incubate for 3 hours at 4°C with gentle rotation

• Perform sequential washes with decreasing detergent concentrations

• Elute bound proteins by:

  • Denaturing: Boiling in SDS sample buffer (for western blot analysis)

  • Native: Using a competing peptide (for activity assays or interaction studies)

Essential controls:

• Input control: Save 5% of pre-cleared lysate for comparison

• IgG control: Perform parallel IP with non-specific IgG of same species/isotype

• Knockout control: Include samples from CYP93G2 T-DNA insertion mutants

• Competing peptide control: Pre-incubate antibody with excess antigen

Modifications for co-immunoprecipitation:

• Use milder detergents (0.1-0.3% NP-40) to preserve protein-protein interactions

• Consider crosslinking techniques for transient interactions

• Include additional controls to confirm specificity of CYP93G2 interaction with partners like OsCGT

• Analyze complexes by mass spectrometry to identify novel interaction partners

This protocol provides a starting point that should be optimized based on the specific properties of the CYP93G2 antibody, the plant material being studied, and the experimental objectives.

How should researchers optimize western blot conditions for CYP93G2 detection?

Optimizing western blot conditions for CYP93G2 detection requires attention to several key parameters:

Sample preparation optimization:

• Extract proteins using buffers compatible with plant tissues:

  • RIPA buffer with plant protease inhibitor cocktail

  • Include 1% PVPP to remove interfering phenolic compounds

  • Add 5 mM DTT to maintain reducing conditions

• Determine optimal protein loading (15-30 μg total protein per lane)

• Heat samples at 95°C for 5 minutes in Laemmli buffer with β-mercaptoethanol

• Include recombinant CYP93G2 as positive control and CYP93G2 T-DNA mutant extracts as negative control

Gel electrophoresis parameters:

• Use 10-12% SDS-PAGE gels (appropriate for the ~58 kDa CYP93G2 protein)

• Run at 100V to ensure good resolution around target molecular weight

• Include pre-stained markers spanning 25-100 kDa range

• Consider gradient gels (4-15%) for better resolution

Transfer optimization:

• Test both PVDF and nitrocellulose membranes

• Optimize transfer conditions:

  • 100V for 1 hour in ice-cold transfer buffer, or

  • 30V overnight at 4°C for larger proteins

• Verify transfer efficiency with reversible Ponceau S staining

• Consider semi-dry versus wet transfer systems based on protein size

Blocking and antibody incubation:

• Test different blocking solutions:

  • 5% non-fat milk in TBS-T (standard)

  • 3-5% BSA in TBS-T (often better for phospho-specific antibodies)

  • Commercial plant-optimized blocking solutions

• Optimize primary antibody concentration through titration (typically 1:500 to 1:5000)

• Incubate with primary antibody overnight at 4°C with gentle agitation

• Use extended washing steps (5-6 washes, 10 minutes each) with TBS-T

Detection system selection:

• For low abundance detection, use enhanced chemiluminescence (ECL) systems

• For quantitative analysis, consider fluorescent secondary antibodies

• Optimize exposure times to prevent signal saturation

• Use digital imaging systems rather than film for wider linear range

Troubleshooting common issues:

• High background: Increase washing steps, dilute antibodies further

• No signal: Check antibody viability, increase concentration or protein loading

• Multiple bands: Validate specificity with knockout controls, consider membrane stripping and reprobing

Following systematic optimization, researchers should document the protocol in detail to ensure reproducibility across experiments.

What flow cytometry-based approaches can be used to validate CYP93G2 antibody specificity?

Flow cytometry provides a quantitative approach for antibody validation, similar to methods developed for other proteins :

Sample preparation for plant cells:

• Generate protoplasts from rice leaves using enzymatic digestion (cellulase/macerozyme)

• Fix cells with 2-4% paraformaldehyde (15 min, room temperature)

• Permeabilize with 0.1-0.3% Triton X-100 or saponin (10 min, room temperature)

• Wash thoroughly with PBS containing 2% BSA to remove fixative and detergent

Staining protocol optimization:

• Block with 5% normal serum from secondary antibody species (30 min)

• Test antibody titration series to determine optimal concentration

• Incubate with anti-CYP93G2 antibody (60 min, 4°C)

• Wash 3 times with PBS/2% BSA

• Incubate with fluorophore-conjugated secondary antibody (30 min, 4°C)

• Wash 3 times before analysis

Essential controls for validation:

• Positive controls: Protoplasts from tissues known to express CYP93G2

• Negative controls:

  • Protoplasts from CYP93G2 T-DNA insertion mutants

  • Isotype control antibody

  • Secondary antibody-only control

  • Unstained cells for autofluorescence baseline

• Specificity controls:

  • Pre-absorption with recombinant CYP93G2 protein

  • Competitive inhibition with immunizing peptide

Data analysis approach:

• Establish gating strategy:

  • Select intact cells based on forward/side scatter

  • Set fluorescence threshold based on negative controls

  • Use histogram overlays to visualize positive populations

• Quantify specificity parameters:

  • Percentage of positive cells

  • Mean/median fluorescence intensity

  • Signal-to-noise ratio compared to controls

• Apply statistical analysis:

  • Calculate staining index: (MFI positive - MFI negative)/2 × SD of negative

  • Perform t-tests or ANOVA to compare conditions

This flow cytometry-based validation provides quantitative data on antibody specificity and can detect potential cross-reactivity that might be missed by other methods . The approach is particularly valuable for comparing multiple antibody clones or optimization conditions in a high-throughput manner.

What approaches can be used to quantitatively assess CYP93G2 expression levels?

Multiple complementary techniques can provide quantitative data on CYP93G2 expression:

Quantitative Western Blot Analysis:

• Sample standardization:

  • Use consistent extraction procedures and protein quantification methods

  • Include recombinant CYP93G2 standard curve (5-100 ng)

  • Normalize to loading controls (actin, tubulin, or GAPDH)

• Imaging and analysis:

  • Capture images using digital systems with wide dynamic range

  • Measure band intensity using ImageJ or specialized software

  • Plot standard curve and interpolate unknown samples

  • Express data as pg CYP93G2 per μg total protein

Enzyme-Linked Immunosorbent Assay (ELISA):

• Assay development:

  • Optimize antibody pairs for sandwich ELISA format

  • Establish standard curves with purified recombinant CYP93G2

  • Validate assay specificity using CYP93G2 T-DNA mutant samples

• Data analysis:

  • Generate four-parameter logistic standard curve

  • Calculate concentration from absorbance values

  • Present data as ng CYP93G2 per mg total protein or per g fresh weight

  • Determine assay sensitivity (limit of detection) and dynamic range

Flow Cytometry Quantification:

• Calibration approach:

  • Use quantitative fluorescence calibration beads

  • Calculate molecules of equivalent soluble fluorochrome (MESF)

  • Determine antibody binding capacity using microspheres

• Cell-based analysis:

  • Measure mean fluorescence intensity in protoplast populations

  • Compare wild-type to overexpression and knockout samples

  • Correlate with biochemical measurements of enzyme activity

  • Present data as relative expression or absolute molecules per cell

Mass Spectrometry-Based Quantification:

• Targeted proteomics approach:

  • Develop selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) assays

  • Use isotopically labeled peptide standards from CYP93G2

  • Identify proteotypic peptides unique to CYP93G2

• Data analysis:

  • Calculate absolute amounts based on internal standards

  • Compare across tissues or experimental conditions

  • Correlate with C-glycosylflavone accumulation

  • Provide stoichiometric relationships with other pathway components

Each method offers different advantages in terms of sensitivity, throughput, and contextual information. The choice depends on the specific research question, available equipment, and desired precision of quantification.

How can CYP93G2 antibodies be used to investigate the relationship between enzyme expression and metabolite production?

CYP93G2 antibodies can provide valuable insights into the relationship between enzyme expression and C-glycosylflavone production:

• Correlation analysis across tissues and conditions:

  • Quantify CYP93G2 protein levels using optimized western blot or ELISA protocols

  • Simultaneously measure C-glycosylflavone metabolites using LC-MS/MS

  • Calculate Pearson or Spearman correlation coefficients

  • Develop predictive models relating enzyme levels to metabolite accumulation

• Time-course studies during development or stress responses:

  • Track CYP93G2 expression at defined time points using immunological methods

  • Measure corresponding changes in 2-hydroxyflavanones and C-glycosylflavones

  • Determine temporal relationships between enzyme induction and metabolite accumulation

  • Identify potential regulatory checkpoints in the biosynthetic pathway

• Genetic variation analysis:

  • Compare CYP93G2 protein levels across rice varieties or related species

  • Correlate with natural variation in C-glycosylflavone profiles

  • Complement with expression quantitative trait loci (eQTL) studies

  • Identify genetic factors influencing the enzyme-metabolite relationship

• Co-localization with metabolite accumulation:

  • Use immunohistochemistry to map CYP93G2 tissue and cellular localization

  • Perform parallel imaging mass spectrometry to localize C-glycosylflavones

  • Identify specialized cells or tissues with coordinated enzyme expression and metabolite accumulation

  • Correlate with expression of OsCGT, which functions downstream in the same pathway

• Perturbation experiments:

  • Manipulate CYP93G2 expression through overexpression or RNAi approaches

  • Measure resulting changes in metabolite profiles

  • Compare with CYP93G2 T-DNA mutant data showing reduced C-glycosylflavone accumulation

  • Develop mathematical models describing the quantitative relationship

These approaches can reveal rate-limiting steps in the pathway and provide insights into the regulation of flavonoid biosynthesis, potentially informing metabolic engineering strategies to enhance or modify C-glycosylflavone production in crops.